AR111122A1 - Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro - Google Patents
Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuroInfo
- Publication number
- AR111122A1 AR111122A1 ARP180100528A ARP180100528A AR111122A1 AR 111122 A1 AR111122 A1 AR 111122A1 AR P180100528 A ARP180100528 A AR P180100528A AR P180100528 A ARP180100528 A AR P180100528A AR 111122 A1 AR111122 A1 AR 111122A1
- Authority
- AR
- Argentina
- Prior art keywords
- insulin
- sequence
- chain
- polypeptides
- single chain
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 10
- 102000004877 Insulin Human genes 0.000 abstract 7
- 108090001061 Insulin Proteins 0.000 abstract 7
- 229940125396 insulin Drugs 0.000 abstract 3
- 235000018417 cysteine Nutrition 0.000 abstract 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 2
- 239000004026 insulin derivative Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004184 polymer manufacturing process Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un análogo de insulina de cadena única que comprende una secuencia de polipéptidos de insulina de cadena B conectada a una secuencia de polipéptidos de insulina de cadena A por una secuencia de polipéptidos de dominio C. La secuencia de polipéptidos de insulina de cadena B contiene una sustitución de cisteína en la posición B4. La secuencia de polipéptidos de insulina de cadena A contiene una sustitución de cisteína en la posición A10. La secuencia de polipéptidos de dominio C tiene 4 a 11 aminoácidos de largo. El análogo mitiga la actividad desfavorable de este 4º puente de disulfuro en análogos de insulina de dos cadenas convencionales, lo que resulta en una duración de señalización de insulina similar a la de la insulina de tipo salvaje. Un método para el tratamiento de un paciente con diabetes mellitus que comprende la administración de una cantidad fisiológicamente eficaz de la proteína o una de sus sales fisiológicamente aceptables a un paciente. El uso de un análogo de insulina de cadena única de la presente en un dispositivo de administración de insulina (como una bomba o una pluma) o como parte de un proceso de fabricación de polímero en estado fundido a alta temperatura.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762468037P | 2017-03-07 | 2017-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111122A1 true AR111122A1 (es) | 2019-06-05 |
Family
ID=63448061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100528A AR111122A1 (es) | 2017-03-07 | 2018-03-07 | Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11174303B2 (es) |
| AR (1) | AR111122A1 (es) |
| TW (1) | TW201835099A (es) |
| UY (1) | UY37629A (es) |
| WO (1) | WO2018165290A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7203415B2 (ja) * | 2015-12-23 | 2023-01-13 | ケース ウェスタン リザーブ ユニバーシティ | ポリマー溶融物内の超安定型インスリン類似体のカプセル化 |
| US11359001B2 (en) | 2016-12-09 | 2022-06-14 | Akston Biosciences Corporation | Insulin-Fc fusions and methods of use |
| CN113038964B (zh) | 2018-06-29 | 2025-05-27 | 德克拉有限公司 | 超长效胰岛素-fc融合蛋白及使用方法 |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| WO2020061554A1 (en) * | 2018-09-21 | 2020-03-26 | Case Western Reserve University | Site 2 single-chain insulin analogues |
| EP3883957A4 (en) * | 2018-11-19 | 2022-08-17 | Case Western Reserve University | SINGLE-CHAIN INSULIN ANALOGS WITH POLYALANINE C-DOMAIN SUBSEGMENTS |
| EP3969467A4 (en) * | 2019-05-17 | 2023-07-05 | Case Western Reserve University | VARIANT SINGLE STREAM INSULIN ANALOGS |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| EP4007594A4 (en) * | 2019-08-02 | 2023-08-09 | Case Western Reserve University | Premixed ultra-stable single-chain insulin analogue formulations |
| FI4073098T3 (fi) | 2019-12-19 | 2023-11-15 | Akston Biosciences Corp | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| WO2021207599A1 (en) | 2020-04-10 | 2021-10-14 | Akston Biosciences Corporation | Antigen specific immunotherapy for covid-19 fusion proteins and methods of use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| EP4255469A4 (en) * | 2020-12-07 | 2025-01-22 | Case Western Reserve University | ACYLATED SINGLE-CHAIN INSULIN ANALOGUES |
| WO2023004406A2 (en) | 2021-07-23 | 2023-01-26 | Akston Biosciences Corporation | Insulin-fc fusion proteins and methods of use to treat cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3538574B2 (ja) | 1999-09-27 | 2004-06-14 | 株式会社リンレイ | 可剥離性被覆組成物 |
| CA2744558A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| JP6944780B2 (ja) | 2014-01-13 | 2021-10-06 | サーマリン インコーポレイテッド | 速効型インスリン製剤及び医薬送達システム |
| JP7203415B2 (ja) | 2015-12-23 | 2023-01-13 | ケース ウェスタン リザーブ ユニバーシティ | ポリマー溶融物内の超安定型インスリン類似体のカプセル化 |
-
2018
- 2018-03-07 AR ARP180100528A patent/AR111122A1/es unknown
- 2018-03-07 US US16/492,824 patent/US11174303B2/en not_active Expired - Fee Related
- 2018-03-07 WO PCT/US2018/021331 patent/WO2018165290A1/en not_active Ceased
- 2018-03-07 UY UY0001037629A patent/UY37629A/es not_active Application Discontinuation
- 2018-03-07 TW TW107107754A patent/TW201835099A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY37629A (es) | 2018-10-31 |
| WO2018165290A1 (en) | 2018-09-13 |
| TW201835099A (zh) | 2018-10-01 |
| US20200140517A1 (en) | 2020-05-07 |
| US11174303B2 (en) | 2021-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111122A1 (es) | Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro | |
| AR098739A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor de glp-1 / glp (péptido similar al glucagón tipo 1 / glucagón) | |
| AR098740A1 (es) | Análogos del péptido exendina-4 | |
| AR105816A2 (es) | Derivados de exendina-4 funcionalizada | |
| AR061242A1 (es) | Polipeptidos de factor de crecimiento de tipo insulina estabilizada | |
| CL2009001340A1 (es) | Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto. | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| CL2009000017A1 (es) | Analogo de insulina con tiempo de accion plano y prolongado; procedimiento de preparación; uso para tratar diabetes mellitus; producto farmaceutico y formulacion que lo comprende; secuencia nucleotidica que lo codifica; vector; y célula hospedera. | |
| AR105822A1 (es) | Análogos de insulina | |
| HRP20181026T1 (hr) | Dugodjelujuće formulacije inzulina | |
| AR098737A1 (es) | Agonistas duales del receptor de glp-1 / gip | |
| PE20170087A1 (es) | Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon | |
| AR091866A1 (es) | Analogos del glucagon | |
| AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
| BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
| AR092076A1 (es) | Proteinas homodimericas | |
| AR077455A1 (es) | Preparaciones insulinicas de accion lenta | |
| AR116605A1 (es) | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) | |
| Alway et al. | The role of mitochondria in mediation of skeletal muscle repair | |
| MX369511B (es) | Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada. | |
| RU2012123642A (ru) | Аналоги инсулина, содержащие хлорированные аминокислоты | |
| EA201492109A1 (ru) | Композиции активатора глюкокиназы для лечения сахарного диабета | |
| AR109552A1 (es) | Análogos de insulina con afinidad reducida para el receptor de insulina y uso de los mismos | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| WO2016105545A3 (en) | Insulin analogues with enhanced stabilized and reduced mitogenicity |